Juno Diagnostics, a healthcare technology company developing the next generation cell-free DNA-based noninvasive prenatal test solutions announced it has ceased commercial operations, effective immediately.
The company released a statement citing “unforeseen circumstances have led to this difficult decision, and we’re devastated that we can no longer continue our mission-driven work to support expectant mothers like you. As we wind down commercial operations, please know that our team is working diligently to ensure patient data is handled with the utmost care and privacy.”
Juno Diagnostics was founded by an experienced team in 2017 that developed and launched the industry’s first NIPT (noninvasive prenatal testing test) product while at Sequenom. JunoDx’s product offerings for NIPT include a Fetal Gender Test and Pre-Natal Screening Test. The company raised $25M to date.
NVIDIA has been in the news this year via announced partnerships to forward genAI’s use in the pharmaceutical industry. Credit: NurPhoto via Getty Images. The
Femtech: Juno Diagnostics Shuts Down Commercial Operations
by Jasmine Pennic Leave a Comment
What You Should Know:
NVIDIA banks on generative AI to pursue partnerships with biotechs – Pharmaceutical Technology
NVIDIA has been in the news this year via announced partnerships to forward genAI’s use in the pharmaceutical industry. Credit: NurPhoto via Getty Images. The
Lilly takes more actions against unapproved versions of Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Here in
Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus again, but our spirits remain